ライフサイエンスコーパス: ventricular tachycardia

1 , bigeminy; 3, couplets; and 4, nonsustained ventricular tachycardia).

2 lie the mechanism of spontaneous polymorphic ventricular tachycardia.

3 eter ablation for post-myocardial infarction ventricular tachycardia.

4 actory ventricular fibrillation or pulseless ventricular tachycardia.

5 in premature ventricular complexes and focal ventricular tachycardia.

6 o diagnosis in catecholaminergic polymorphic ventricular tachycardia.

7 children with catecholaminergic polymorphic ventricular tachycardia.

8 ome (LQTS) and catecholaminergic polymorphic ventricular tachycardia.

9 diseases, such as malignant hyperthermia and ventricular tachycardia.

10 ion in LQTS or catecholaminergic polymorphic ventricular tachycardia.

11 on inflammation), there were 680 episodes of ventricular tachycardia.

12 ck excluding right ventricular outflow tract ventricular tachycardia.

13 utaneous epicardial mapping and ablation for ventricular tachycardia.

14 pertrophy, and catecholaminergic polymorphic ventricular tachycardia.

15 on epicardial scar can facilitate re-entrant ventricular tachycardia.

16 port and antitachycardia pacing to terminate ventricular tachycardia.

17 esistant ventricular fibrillation /pulseless ventricular tachycardia.

18 s had a combined history of 6577 episodes of ventricular tachycardia.

19 uided, noninvasive cardiac radioablation for ventricular tachycardia.

20 radioablation markedly reduced the burden of ventricular tachycardia.

21 ever, had more hypertrophy, and nonsustained ventricular tachycardia.

22 hythmogenic substrate and critical sites for ventricular tachycardia.

23 heter ablation of post-myocardial infarction ventricular tachycardia.

24 All the 9 ventricular tachycardias (100%) terminated with adenosin

25 Among 16 critical sites for ventricular tachycardia, 3 (18%) were in a discordant re

26 Of the 9 patients with sustained annular ventricular tachycardia, 3 were localized to the tricusp

27 a syndrome, 8; catecholaminergic polymorphic ventricular tachycardia, 3; short QT syndrome, 1; and ar

28 yndrome (13%), catecholaminergic polymorphic ventricular tachycardia (4%), arrhythmogenic right ventr

29 Of these, 177 (28.8%) had idiopathic ventricular tachycardia, 408 (66.5%) had symptomatic PVC

30 tors (18; 38%; catecholaminergic polymorphic ventricular tachycardia [6], near-drowning [2], exertion

31 cular tachycardia recurrence can occur after ventricular tachycardia ablation because of incomplete a

32 of consecutive patients who underwent EA for ventricular tachycardia ablation or Lariat procedure usi

33 This catheter shows promise for decreasing ventricular tachycardia ablation procedure time and impr

34 ents referred for post-myocardial infarction ventricular tachycardia ablation were included.

35 al aortic valves, who underwent scar-related ventricular tachycardia ablation, were analyzed to corre

36 Future studies will focus on ventricular tachycardia ablation; preliminary data sugge

37 sustained ventricular tachycardia, sustained ventricular tachycardia, aborted sudden cardiac death, o

38 actory ventricular fibrillation or pulseless ventricular tachycardia after at least one shock, and va

39 Recurrent ventricular tachycardia among survivors of myocardial in

40 underwent catheter ablation for focal VA (11 ventricular tachycardia and 19 premature contractions) w

41 Noninvasive analysis of ventricular tachycardia and early VF in patients with Br

42 sk factor for sudden cardiac death caused by ventricular tachycardia and fibrillation (VT/VF).

43 useful for selecting ablation targets during ventricular tachycardia and for substrate mapping.

44 eases, such as catecholaminergic polymorphic ventricular tachycardia and heart failure (HF).

45 A history of ventricular tachycardia and left ventricular dysfunction

46 tablished were catecholaminergic polymorphic ventricular tachycardia and long QT syndrome (17 [6%] an

47 minant role of catecholaminergic polymorphic ventricular tachycardia and long QT syndrome, especially

48 Ventricular tachycardia and premature ventricular comple

49 Catheter ablation for ventricular tachycardia and premature ventricular comple

50 able arrest rhythm (ventricular fibrillation/ventricular tachycardia), and ST-elevations-had excellen

51 associated high risk of sudden death due to ventricular tachycardia, and congenital bilateral deafne

52 for age, sex, left atrial size, nonsustained ventricular tachycardia, and ejection fraction.

53 odynamically tolerated sustained monomorphic ventricular tachycardia, and male sex predicted lethal a

54 fraction <45% and sustained or nonsustained ventricular tachycardia as independent risk factors.

55 fficacy was assessed by counting episodes of ventricular tachycardia, as recorded by ICDs.

56 Patients with sustained monomorphic ventricular tachycardia associated with coronary disease

57 wild-type and catecholaminergic polymorphic ventricular tachycardia-associated RyR2(R4496C+/-) heart

58 s of appropriate shock included nonsustained ventricular tachycardia, atrial fibrillation, serum crea

59 lanted for a positive (inducible monomorphic ventricular tachycardia) but not a negative (no inducibl

60 actory ventricular fibrillation or pulseless ventricular tachycardia, but without proven survival ben

61 able (ventricular fibrillation and pulseless ventricular tachycardia) cardiac arrests.

62 In 2 ventricular tachycardia cases, absence of PN capture was

63 mes, including catecholaminergic polymorphic ventricular tachycardia, congenital long QT syndrome, an

64 mparison, phase sequences during monomorphic ventricular tachycardia correlated moderately with VF (P

65 ssociated with catecholaminergic polymorphic ventricular tachycardia (CPVT) and atrial fibrillation (

66 thmias such as catecholaminergic polymorphic ventricular tachycardia (CPVT) and long QT syndrome.

67 ome (LQTS) and catecholaminergic polymorphic ventricular tachycardia (CPVT) are electric diseases cha

68 Catecholaminergic polymorphic ventricular tachycardia (CPVT) causes sudden cardiac dea

69 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a condition of abnorma

70 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a genetic disorder cau

71 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentially lethal g

72 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmi

73 flecainide for catecholaminergic polymorphic ventricular tachycardia (CPVT) is unclear.

74 al features of catecholaminergic polymorphic ventricular tachycardia (CPVT) or long QT syndrome (LQTS

75 ome (LQTS) and catecholaminergic polymorphic ventricular tachycardia (CPVT) represent treatable cause

76 thmogenesis in catecholaminergic polymorphic ventricular tachycardia (CPVT) require spontaneous Ca(2+

77 cause dominant catecholaminergic polymorphic ventricular tachycardia (CPVT), a leading cause of sudde

78 In catecholaminergic polymorphic ventricular tachycardia (CPVT), cardiac Purkinje cells (

79 ation (AF) and catecholaminergic polymorphic ventricular tachycardia (CPVT).

80 h-predisposing catecholaminergic polymorphic ventricular tachycardia (CPVT).

81 T syndrome and catecholaminergic polymorphic ventricular tachycardia (CPVT).

82 sudden death (catecholaminergic polymorphic ventricular tachycardia [CPVT]).

83 h ischemic cardiomyopathy and an ICD who had ventricular tachycardia despite antiarrhythmic drug ther

84 h ischemic cardiomyopathy and an ICD who had ventricular tachycardia despite the use of antiarrhythmi

85 eart block, bradycardia, supraventricular or ventricular tachycardia) developed.

86 vs. 0/10 Kcne3(+/+) mice exhibited sustained ventricular tachycardia during reperfusion (P<0.05).

87 Following myocardial infarction, spontaneous ventricular tachycardia episodes (n = 3) were preceded b

88 rome (1/2) and catecholaminergic polymorphic ventricular tachycardia families (1/2) who were tested.

89 aneous early afterdepolarizations (EADs) and ventricular tachycardia/fibrillation occurred in 50% of

90 sudden cardiac death (SCD) may be caused by ventricular tachycardia/fibrillation or pulseless electr

91 In 319 patients with ventricular tachycardia/fibrillation out-of-hospital car

92 N-92, abolished EADs and hypokalemia-induced ventricular tachycardia/fibrillation, as did the selecti

93 en cardiac arrest (SCA) due to ECG-confirmed ventricular tachycardia/fibrillation, as seen in a commu

94 CD discharge for ventricular fibrillation or ventricular tachycardia >240 beats/min.

95 or discharge for ventricular fibrillation or ventricular tachycardia >240 bpm) and 36 nonsudden cardi

96 d left ventricular function but no inducible ventricular tachycardia have a favorable long-term progn

97 resistant ventricular fibrillation/pulseless ventricular tachycardia; however, the efficacy of AMD in

98 odynamically tolerated sustained monomorphic ventricular tachycardia (HR: 2.19; p = 0.023), and male

99 g QT syndrome, catecholaminergic polymorphic ventricular tachycardia, hypertrophic cardiomyopathy, an

100 ck or severe bradycardia in 24, nonsustained ventricular tachycardia in 26, and intermittent left bun

101 ectopic activity and enhanced substrates for ventricular tachycardia in failing, but not in donor, he

102 at azithromycin can cause rapid, polymorphic ventricular tachycardia in the absence of QT prolongatio

103 d cells, (2) reduced adrenergically mediated ventricular tachycardia in treated mice, (3) reverted ul

104 nterval prolongation and increased number of ventricular tachycardias induced were also associated wi

105 eath, resuscitated cardiac arrest, sustained ventricular tachycardia, insertion of a pacemaker or imp

106 Catecholaminergic polymorphic ventricular tachycardia is an uncommon, potentially leth

107 Post-infarct ventricular tachycardia is associated with channels of s

108 A common strategy for ablation of scar-based ventricular tachycardia is delivering multiple lesions i

109 Although the rate of idiopathic ventricular tachycardia is similar across sexes, women h

110 t or documented ventricular fibrillation and ventricular tachycardia (lasting >/=30 seconds or recurr

111 to the onset of ventricular fibrillation and ventricular tachycardia, leading to life-threatening arr

112 ction, electrophysiology study, nonsustained ventricular tachycardia, left bundle branch block, signa

113 ice carrying a catecholaminergic polymorphic ventricular tachycardia-linked RyR2 mutation (A4860G) sh

114 nce of chronic renal disease or nonsustained ventricular tachycardia, low-income prescription benefit

115 Left posterior fascicular ventricular tachycardia (LPF-VT) is frequently misdiagno

116 chest pain and ECG changes after epicardial ventricular tachycardia mapping and ablation.

117 or via twin atrioventricular nodes (n = 4), ventricular tachycardia (n = 5), and undefined atrial ta

118 cardiac defibrillator shock (n=4), sustained ventricular tachycardia (n=1), or sudden death (n=1), co

119 2), organized rhythm (n=120), or monomorphic ventricular tachycardia (n=4).

120 QTS (N=40) and catecholaminergic polymorphic ventricular tachycardia (N=7) underwent video-assisted t

121 s (1%) had minor complications (nonsustained ventricular tachycardia [n=1], fast paroxysmal atrial fi

122 ry direct ERT notification for 105 patients (ventricular tachycardia, n = 44; pause/asystole, n = 36;

123 ion was performed exclusively in 6 patients (ventricular tachycardia, n=1; PVC, n=5).

124 LV ablation was performed in 12 patients (ventricular tachycardia, n=2; PVC, n=10) and right ventr

125 In five patients with refractory ventricular tachycardia, noninvasive treatment with elec

126 The prognostic significance of nonsustained ventricular tachycardia (NSVT) in patients with hypertro

127 Nonsustained ventricular tachycardia (NSVT) is common after acute cor

128 syncope, atrial fibrillation, non-sustained ventricular tachycardia (nsVT), maximum left ventricular

129 atic event of multiple beats of nonsustained ventricular tachycardia (NSVT).

130 Previous ventricular tachycardia occurred in 16 patients (8%) and

131 A reduction in episodes of ventricular tachycardia occurred in all five patients.

132 A 58-year-old woman presenting with a ventricular tachycardia of 190 beats/min was administere

133 iency profoundly decreased vulnerability for ventricular tachycardia on programmed right ventricular

134 t did not terminate a spontaneous episode of ventricular tachycardia or fibrillation).

135 e men, and 83 (54%) had an initial rhythm of ventricular tachycardia or fibrillation.

136 achycardia) but not a negative (no inducible ventricular tachycardia or inducible ventricular fibrill

137 ogy of Fallot undergoing PVR with history of ventricular tachycardia or left ventricular dysfunction

138 ardiac arrest (OHCA) with initial rhythms of ventricular tachycardia or pulseless ventricular fibrill

139 atients meeting study criteria scheduled for ventricular tachycardia or PVC ablation over a 9-month p

140 hospital or emergency admission because of a ventricular tachycardia or reablation) occurred in 14 pa

141 tients who underwent EpiAcc for ablation for ventricular tachycardia or symptomatic premature ventric

142 Prompt defibrillation for IHCA caused by ventricular tachycardia or ventricular fibrillation was

143 Patients with IHCA caused by pulseless ventricular tachycardia or ventricular fibrillation were

144 itated arrest, successful defibrillation for ventricular tachycardia or ventricular fibrillation) wer

145 Of 8119 patients with an IHCA caused by ventricular tachycardia or ventricular fibrillation, the

146 ients had a successful conversion of induced ventricular tachycardia or ventricular fibrillation.

147 electrical storm (ES), in which a cluster of ventricular tachycardias or ventricular fibrillation, ne

148 c death, ventricular fibrillation, sustained ventricular tachycardia, or arrhythmogenic syncope.

149 cause of ventricular fibrillation, pulseless ventricular tachycardia, or unknown shockable rhythm bet

150 ient) adjacent to the right PN or epicardial ventricular tachycardia origin adjacent to the left PN (

151 thesis in patients with sustained atrial and ventricular tachycardia originating from the peri-tricus

152 imary outcome was a combined event including ventricular tachycardia, out-of-hospital cardiac arrest,

153 ek blanking period, there were 4 episodes of ventricular tachycardia over the next 46 patient-months,

154 ohort study of catecholaminergic polymorphic ventricular tachycardia patients diagnosed before 19 yea

155 A total of 45 ventricular tachycardias/premature ventricular complexes

156 Respiratory failure, persistent ventricular tachycardia, profound shock refractory to in

157 Mapping to identify scar-related ventricular tachycardia re-entry circuits during sinus r

158 T syndrome and catecholaminergic polymorphic ventricular tachycardia received routine beta-blocker th

159 tachycardia patients; however, a nontargeted ventricular tachycardia recurred in 1 patient at a media

160 tients post ablation, and 71% remain free of ventricular tachycardia recurrence at 6-month median fol

161 Ventricular tachycardia recurrence can occur after ventr

162 tion duration, 6-month sustained monomorphic ventricular tachycardia recurrence, quality of life meas

163 ncy ablation of the arrhythmic focus without ventricular tachycardia recurrence.

164 84) of patients had no sustained monomorphic ventricular tachycardia recurrence; the proportion of pa

165 icardial radiofrequency catheter ablation of ventricular tachycardia remains challenging because of t

166 Notably, recurrent monomorphic ventricular tachycardia requiring >/=2 implantable cardi

167 o our institution with recurrent episodes of ventricular tachycardia requiring emergent total artific

168 ode of ventricular fibrillation or sustained ventricular tachycardia requiring external cardioversion

169 as the composite of sudden cardiac death and ventricular tachycardia requiring treatment constituted

170 redistribution of gap junctions and promotes ventricular tachycardia, showing the functional signific

171 of ventricular tachycardia within 24 hours (ventricular tachycardia storm), or appropriate ICD shock

172 e of the composite primary outcome of death, ventricular tachycardia storm, or appropriate ICD shock

173 th 1; one (10%) patient died after incessant ventricular tachycardia storm, which led to terminal hea

174 CC causes a unique ventricular tachycardia substrate concentrated to the ba

175 nt endocardial and epicardial regions during ventricular tachycardia substrate mapping using a CF-sen

176 e of value to treat intramural or epicardial ventricular tachycardia substrates resistant to conventi

177 and SCN5A) and catecholaminergic polymorphic ventricular tachycardia-susceptibility gene (RYR2) ident

178 osite end point of long runs of nonsustained ventricular tachycardia, sustained ventricular tachycard

179 Nonsustained ventricular tachycardia, syncope, a family history of su

180 , Brugada, and catecholaminergic polymorphic ventricular tachycardia syndromes) should also be consid

181 ases linked to catecholaminergic polymorphic ventricular tachycardia that feature lethal cardiac arrh

182 invasive electrocardiographic imaging during ventricular tachycardia that was induced by means of an

183 Both in atrial tachycardia and ventricular tachycardia, the variation in difference bet

184 In 8 mapped reentrant ventricular tachycardias, the circuits included regions

185 mmed to high-rate cut-off (Arm B) or delayed ventricular tachycardia therapy (Arm C), compared with c

186 High-rate cut-off or delayed ventricular tachycardia therapy programming significantl

187 In idiopathic ventricular tachycardia, there was an increase in incide

188 for Endocardial RF Ablation in Patients With Ventricular Tachycardia [THERMOCOOL VT]; NCT00412607).

189 ployed this optical system in the setting of ventricular tachycardia to optimize mechanistic, multi-b

190 the morphologically distinctive polymorphic ventricular tachycardia ('torsades de pointes').

191 Catecholaminergic polymorphic ventricular tachycardia type 2 (CPVT2) results from auto

192 patients with coronary disease and recurrent ventricular tachycardia undergoing catheter ablation, we

193 actory premature ventricular contractions or ventricular tachycardia underwent catheter cryoablation

194 15, five patients with high-risk, refractory ventricular tachycardia underwent treatment.

195 tients referred for ablation of scar-related ventricular tachycardia underwent voltage maps during a

196 T-3), hypertrophic cardiomyopathy (HCM), and ventricular tachycardia-ventricular fibrillation (VT-VF)

197 ICD discharge-free survival for ventricular tachycardia/ventricular fibrillation >/= 240

198 unger (53.7 vs 62.7 yr; p < 0.001), had more ventricular tachycardia/ventricular fibrillation (81% vs

199 unnecessary therapy but permits therapy for ventricular tachycardia/ventricular fibrillation (VF).

200 ST-segment elevation in 26.1%, and 3.6% had ventricular tachycardia/ventricular fibrillation arrest.

201 ICD termination of rapid ventricular tachycardia/ventricular fibrillation can rea

202 Patients with repetitive ventricular tachycardia/ventricular fibrillation episode

203 Each ES episode included a median of 7 ventricular tachycardia/ventricular fibrillation episode

204 strate reduces or prevents the recurrence of ventricular tachycardia/ventricular fibrillation in such

205 of abnormal substrate, BrS ECG pattern, and ventricular tachycardia/ventricular fibrillation inducib

206 lted in BrS ECG pattern disappearance and no ventricular tachycardia/ventricular fibrillation inducib

207 extent of abnormal epicardial substrate, and ventricular tachycardia/ventricular fibrillation inducib

208 During ischemia, ventricular tachycardia/ventricular fibrillation inducib

209 Yet the majority of SCD-ventricular tachycardia/ventricular fibrillation occurs

210 meet the primary end point of time to first ventricular tachycardia/ventricular fibrillation recurre

211 rdiac arrest patients with initial rhythm of ventricular tachycardia/ventricular fibrillation was 56%

212 emales, determine whether ICD discharges for ventricular tachycardia/ventricular fibrillation were eq

213 ia (resuscitated cardiac arrest or sustained ventricular tachycardia/ventricular fibrillation).

214 in; p < 0.001) and less often presented with ventricular tachycardia/ventricular fibrillation, a witn

215 end point of time to death, ischemic stroke, ventricular tachycardia/ventricular fibrillation, and he

216 n = 44; pause/asystole, n = 36; polymorphic ventricular tachycardia/ventricular fibrillation, n = 14

217 wing events: cardiac death, ischemic stroke, ventricular tachycardia/ventricular fibrillation, or hea

218 nd point was the time to first recurrence of ventricular tachycardia/ventricular fibrillation.

219 ad non-ST-segment elevation MI, and 8.9% had ventricular tachycardia/ventricular fibrillation.

220 and novel risk stratification tools for SCD-ventricular tachycardia/ventricular fibrillation.

221 ch in risk stratification has focused on SCD-ventricular tachycardia/ventricular fibrillation.

222 rhythms (ventricular fibrillation/pulseless ventricular tachycardia [VF/VT]) during resuscitation.

223 y (premature ventricular complexes (PVCs) or ventricular tachycardia (VT >/= 3 beats)).

224 ctrophysiologic procedures in the context of ventricular tachycardia (VT) (n = 9), Wolff-Parkinson-Wh

225 s frequently used as procedural end point of ventricular tachycardia (VT) ablation after myocardial i

226 Outcomes of ventricular tachycardia (VT) ablation have been describe

227 Data on the outcomes of ventricular tachycardia (VT) ablation in nonischemic dil

228 Epicardial ventricular tachycardia (VT) ablation is associated with

229 Substrate-based mapping for ventricular tachycardia (VT) ablation is hampered by its

230 However, the effect of ventricular tachycardia (VT) ablation on global and regi

231 t devices for hemodynamic support during the ventricular tachycardia (VT) ablation procedure are limi

232 igger/substrate modifier not used in current ventricular tachycardia (VT) ablation strategies.

233 ng the CARTOUNIVU module during scar-related ventricular tachycardia (VT) ablation.

234 ents with ischemic heart disease (IHD) after ventricular tachycardia (VT) ablation.

235 Recurrence of ventricular tachycardia (VT) after ablation in patients

236 enation during catheter ablation of unstable ventricular tachycardia (VT) at our center.

237 Radiofrequency ablation (RFA) of ventricular tachycardia (VT) can fail because of inacces

238 -hospital (OH) ventricular fibrillation (VF)/ventricular tachycardia (VT) cardiac arrest is unknown.

239 In vivo description of ventricular tachycardia (VT) circuits is limited by insu

240 functionally most specific for scar-related ventricular tachycardia (VT) circuits.

241 Catheter ablation for ventricular tachycardia (VT) from structural heart disea

242 Inducibility of ventricular tachycardia (VT) has limited ability to pred

243 ofrequency catheter ablation of scar-related ventricular tachycardia (VT) has not been previously inv

244 Catheter ablation of ventricular tachycardia (VT) in arrhythmogenic right ven

245 s catheter ablation of sustained monomorphic ventricular tachycardia (VT) in LMNA cardiomyopathy.

246 Catheter ablation (CA) of ventricular tachycardia (VT) in patients with cardiac sa

247 Catheter ablation (CA) of ventricular tachycardia (VT) in patients with nonischemi

248 Data on outcomes after catheter ablation of ventricular tachycardia (VT) in patients with nonischemi

249 Radiofrequency catheter ablation (RFCA) of ventricular tachycardia (VT) in repaired Tetralogy of Fa

250 Ventricular tachycardia (VT) is a major cause of sudden

251 Cardiac sarcoid-related ventricular tachycardia (VT) is a rare disorder; the und

252 Inducible ventricular tachycardia (VT) is a strong predictor of sp

253 Ventricular tachycardia (VT) is an important cause of la

254 Catheter ablation of ventricular tachycardia (VT) is being increasingly perfo

255 o the lateral boundary (LB) of the reentrant ventricular tachycardia (VT) isthmus or diastolic pathwa

256 ons found in nonischemic cardiomyopathy with ventricular tachycardia (VT) morphology, late potential

257 potential (LP) abolition and postprocedural ventricular tachycardia (VT) noninducibility constitute

258 l abnormal ventricular activities (LAVA) and ventricular tachycardia (VT) noninducibility.

259 l for catheter ablation (CA) of scar-related ventricular tachycardia (VT) on acute success, VT recurr

260 The end point was the first event of ventricular tachycardia (VT) or fibrillation (VF).

261 Ventricular tachycardia (VT) radiofrequency ablation has

262 Ventricular tachycardia (VT) refractory to antiarrhythmi

263 Ventricular tachycardia (VT) substrate ablation usually

264 of slow-conducting channels that may act as ventricular tachycardia (VT) substrate.

265 are often short with multiple side branches, ventricular tachycardia (VT) supporting channels have ve

266 In contrast to ventricular tachycardia (VT) that occurs in the setting

267 al benefit in post-infarction patients whose ventricular tachycardia (VT) was rendered noninducible b

268 ment (LGE), (2) quantify their risk of death/ventricular tachycardia (VT), and (3) identify imaging-b

269 Adverse events (AE)-death or sustained ventricular tachycardia (VT)-were ascertained by electro

270 ions in the CACNA1C gene are associated with ventricular tachycardia (VT).

271 lico approach for simulating infarct-related ventricular tachycardia (VT).

272 n in postmyocardial infarction patients with ventricular tachycardia (VT).

273 (RF) delivery in patients with scar-related ventricular tachycardia (VT).

274 ight ventricular pathological remodeling and ventricular tachycardia (VT).

275 catheter ablation is used to treat recurrent ventricular tachycardia (VT).

276 ere enrolled: 63 (group 1) having documented ventricular tachycardia (VT)/ventricular fibrillation (V

277 ts (8%) without NSVT experienced ICD-treated ventricular tachycardia (VT)/ventricular fibrillation (V

278 d enhancement (DE) on MRI is associated with ventricular tachycardia (VT)/ventricular fibrillation or

279 on therapy ICDs, history of >/=1 ICD-treated ventricular tachycardias (VT)/ventricular fibrillation e

280 frequency ablation of multiple or unmappable ventricular tachycardias (VTs) remains a challenge with

281 d treatment modality for a broad spectrum of ventricular tachycardias (VTs).

282 One hundred and ten ventricular tachycardias (VTs; cycle lengths, 230-740 ms

283 mposite incidence of sudden cardiac death or ventricular tachycardia was 41% at 1 year and 55% at 5 y

284 estored to normal level and the induction of ventricular tachycardia was abolished by RAGE silencing.

285 Confirmatory of prior work, inducible ventricular tachycardia was associated with a larger epi

286 The diastolic isthmus in ventricular tachycardia was mapped in 3 patients and col

287 Ventricular tachycardia was noninducible in 85% of patie

288 Ventricular tachycardia was re-entrant in all.

289 thm of ventricular fibrillation or pulseless ventricular tachycardia was refractory to shock.

290 arate data set (12 atrial tachycardia and 10 ventricular tachycardia), we evaluated for each method t

291 omyopathy, and catecholaminergic polymorphic ventricular tachycardia were the most common diagnoses.

292 ith large pleural effusions and another with ventricular tachycardia, were not successfully gated.

293 d ablation of right ventricular scar-related ventricular tachycardia with computed tomographic image

294 fraction <45% and sustained or nonsustained ventricular tachycardia with hazard ratios of 4.0 (95% c

295 /=1 couplet or (2) sustained or nonsustained ventricular tachycardia with left bundle branch block ex

296 ythmia syndrome characterized by polymorphic ventricular tachycardia with physical or emotional stres

297 icular fibrillation and those with sustained ventricular tachycardia with syncope or systolic heart f

298 death, three or more documented episodes of ventricular tachycardia within 24 hours (ventricular tac

299 shocks triggered at heart rates >/= 170 bpm (ventricular tachycardia zone) and at rates >/= 200 bpm (

300 that restrict therapy to regular rhythms in ventricular tachycardia zones.